Correction to: Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review

被引：0
|
作者：
Caleb J. Smith
Yahya Almodallal
Aminah Jatoi
机构：
[1] Mayo Clinic,Department of Medicine
[2] Mayo Clinic,Department of Oncology
来源：
Current Oncology Reports | 2021年 / 23卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A Correction to this paper has been published: https://doi.org/10.1007/s11912-021-01101-2
引用
收藏
相关论文
共 50 条
  • [1] Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review
    Caleb J. Smith
    Yahya Almodallal
    Aminah Jatoi
    [J]. Current Oncology Reports, 2021, 23
  • [2] Rare Adverse Events with Programmed Death-1 and Programmed Death-1 Ligand Inhibitors: Justification and Rationale for a Systematic Review
    Smith, Caleb J.
    Almodallal, Yahya
    Jatoi, Aminah
    [J]. CURRENT ONCOLOGY REPORTS, 2021, 23 (07)
  • [3] Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review (vol 23, 86, 2021)
    Smith, Caleb J.
    Almodallal, Yahya
    Jatoi, Aminah
    [J]. CURRENT ONCOLOGY REPORTS, 2021, 23 (08)
  • [4] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma
    Cheah, Chan Yoon
    Fowler, Nathan H.
    Neelapu, Sattva S.
    [J]. CURRENT OPINION IN ONCOLOGY, 2015, 27 (05) : 384 - 391
  • [5] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
    Wang, Tianyu
    Wu, Xiaoxing
    Guo, Changying
    Zhang, Kuojun
    Xu, Jinyi
    Li, Zheng
    Jiang, Sheng
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (04) : 1715 - 1730
  • [6] OCULAR ADVERSE EVENTS ASSOCIATED WITH PROGRAMMED DEATH-1 AND PROGRAMMED DEATH LIGAND-1 IMMUNOTHERAPY
    Young, LeAnne
    Finnigan, Shanda
    Streicher, Howard
    Chen, Helen
    Murray, James
    Sen, H. Nida
    Sharon, Elad
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A386 - A387
  • [7] Programmed Death-1 and Programmed Death-Ligand 1 Expression Patterns in Pediatric Lymphoma
    Tamura, Akihiro
    Yoshida, Makiko
    Yamamoto, Nobuyuki
    Nino, Nanako
    Nakatani, Naoko
    Ichikawa, Takayuki
    Nakamura, Sayaka
    Saito, Atsuro
    Kozaki, Aiko
    Kishimoto, Kenji
    Ishida, Toshiaki
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    [J]. BLOOD, 2018, 132
  • [8] Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
    Liu Qiang
    Li Chun-Sheng
    [J]. 中华医学杂志(英文版), 2017, (08) : 986 - 992
  • [9] Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
    Liu, Qiang
    Li, Chun-Sheng
    [J]. CHINESE MEDICAL JOURNAL, 2017, 130 (08) : 986 - 992
  • [10] Incidence and risk of colitis with programmed death-1 versus programmed death-ligand 1 inhibitors for the treatment of cancer.
    Miyashita, Hirotaka
    Mikami, Takahisa
    Satoi, Sera
    Cruz, Christina
    Galsky, Matt D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345